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Abstract (word count: 250) 
Background 
 Enhanced recovery after surgery (ERAS) programs have been shown to ease the 
postoperative recovery and improve clinical outcomes for various surgery types. ERAS cost-
effectiveness was demonstrated for colorectal surgery but not for liver surgery. The present 
study aim was to analyze the implementation costs and benefits of a specific ERAS program 
in liver surgery.  
Methods  
 A dedicated ERAS protocol for liver surgery was implemented in our department in 
July 2013. The subsequent year all consecutive patients undergoing liver surgery were treated 
according to this protocol (ERAS group). They were compared in terms of real in-hospital 
costs with a patient series before ERAS implementation (pre-ERAS group). Mean costs per 
patient were compared with a bootstrap T-test. A cost-minimization analysis was performed.  
Results 
 Seventy-four ERAS patients were compared with 100 pre-ERAS patients. There were 
no significant pre- and intraoperative differences between the two groups, except for the 
laparoscopy number (n=18 ERAS, n=9 pre-ERAS, p=0.010). Overall postoperative 
complications were observed in 36 (49%) and 64 patients (64%) in the ERAS and pre-ERAS 
groups, respectively (p=0.046). The median length of stay was significantly shorter for the 
ERAS group (8 vs. 10 days, p=0.006). 
 The total mean costs per patient were €38’726 and €42’356 for ERAS and pre-ERAS 
(p=0.467). The cost-minimization analysis showed a total mean cost reduction of €3’080 per 
patient after ERAS implementation.  
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Conclusions 
 ERAS implementation for liver surgery induced a non-significant decrease in cost 
compared to standard care. Significant decreased complication rate and hospital stay were 
observed in the ERAS group.  
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Introduction 
 Enhanced recovery after surgery (ERAS) programs are standardized multimodal 
perioperative care aiming to reduce the patient’s response to surgical stress and to decrease 
the postoperative complication risk [1]. Fewer postoperative complications and improved 
recovery lead to a shorter length of hospital stay (LoS). ERAS has been shown to be 
beneficial on a clinical and economic level in colorectal surgery [2–4]. Therefore, ERAS 
programs have been extended to other types of surgery, including liver surgery [5–10], but 
few studies compared an ERAS pathway for liver surgery to a conventional perioperative 
management [11–14]. The preliminary results have shown that ERAS for liver surgery 
appears to be safe and feasible [12–17]. Moreover, some studies showed a diminution of 
postoperative complications or LoS [18–20]. 
 Formal guidelines for ERAS in liver surgery have not been published yet. However, 
general recommendations for ERAS in liver surgery based on ERAS protocol in pancreas 
surgery [21] encompass the use of preoperative counseling, carbohydrate beverages, reduced 
preoperative fasting, optimized fluid balance, avoidance of premedication, standardized 
postoperative analgesia, early postoperative nutrition, and early postoperative mobilization. 
 While implementing a new clinical perioperative pathway should first and foremost 
result in clinical benefits for the patients, it should also be preferentially cost-beneficial in 
order to convince the financial hospital authorities to invest in such a project and to contribute 
to reduce the health care costs.  
 The study aim was to compare the complete real in-hospital costs for liver resections 
before and after systematic implementation of an ERAS pathway for liver surgery in an 
ERAS-dedicated tertiary center. 
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Material and Methods 
ERAS protocol and patient groups  
 ERAS was first implemented for colorectal surgery in our department in May 2011. 
The members of the multidisciplinary team had received beforehand a formal training 
provided by the ERAS® Society. ERAS protocol for liver surgery was implemented in the 
department of Visceral Surgery at the University Hospital of Lausanne (CHUV, Switzerland) 
in July 2013. This protocol was developed by the local ERAS team based on previous ERAS 
protocols for pancreas [21] and colorectal [22] surgery. This liver protocol encompasses a list 
of diverse pre-, intra-, and postoperative items that are summarized in detail in Table 1.  
 From July 2013 to July 2014 all consecutive liver resections were included into 
ERAS. Major hepatectomy was defined as resection of ≥3 Couinaud segments, and minor 
hepatectomy as resection of one to two liver segments. Wedge resections were defined as 
non-anatomical partial resections of liver segments.  
 The ERAS group (from July 2013 to July 2014) was compared to a pre-ERAS group 
that included a cohort of 100 consecutive patients who underwent liver surgery before the 
implementation of ERAS for liver surgery. No power analysis was performed because it was 
estimated a priori that selecting a cohort of 70 to 80 consecutive ERAS patients would permit 
to draw a firm statistically-based conclusion. 
 The study was retrospective. However, all data were prospectively recorded in our 
liver database for both periods, prior and after ERAS implementation. Data collection was 
performed by a dedicated and fully trained ERAS nurse. The study was approved by the local 
ethics committee (protocol number 362/14) and was registered online on Research Registry 
(UIN: researchregistry443). 
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Perioperative parameters 
 Operating time was calculated from incision to skin closure, whereas anesthesia time 
was calculated from the patient entry in the operating room (OR) until the patient was awake. 
Postoperative complications were graded according to the validated Clavien classification 
[23] and the comprehensive complication index (CCI) [24]. Grade I-II were defined as minor 
complications and grade III-IV as major complications [23]. Postoperative death during the 
hospital stay or during the 30 postoperative days was defined as grade V [23]. Formal ERAS 
validated discharge criteria were: control of pain with oral analgesia only, no intravenous 
fluids, independent mobilization, and sufficient oral intake (at least 2/3 of a normal meal). 
LoS was defined from operation day until day of discharge. Data about readiness for 
discharge were not collected. Even though readiness for discharge is more realistic than LoS, 
this concept may be more subjective (based on doctors’ appreciations) than the actual hospital 
LoS. That is why LoS was calculated based on objective figures. Readmission rate was 
defined as the number of patients needing a rehospitalization within 60 days of surgery. 
Overall compliance was calculated as the number of fulfilled pre-, intra-, and postoperative 
items divided by the total number of predefined enhanced recovery measures (expressed in 
%). For the pre-ERAS group, it was assessed if some ERAS items were already applied, and 
overall compliance was then calculated. 
Analysis of the costs 
 A comprehensive analysis of all real costs was performed for every patient according 
to a method previously used by our group [3]. Briefly, all pertinent intraoperative costs and 
pre-/postoperative costs were considered. The intraoperative costs included the disposable 
material used during the operation and the anesthesia as well as OR costs. The anesthesia 
costs integrated the anesthesiologist and anesthesia nurse costs (based on the duration of the 
anesthesia in minutes) as well as the materials and medications used for the anesthesia. The 
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OR costs were based on the OR occupation in minutes. The pre- and postoperative costs 
included the following items: intensive care unit (ICU)/intermediate care (IC), medical care, 
nursing care, physiotherapy, medication, blood test, laboratory, radiology, pathology, 
housing, administration, and other costs. The medical care costs included all costs related to 
the doctors’ clinical activities, except for the anesthesiologist costs accounted in the 
anesthesia and OR costs. The costs of nursing care represented the costs of the ward and did 
not include the ICU and IC costs. They were based on the Project of Research in Nursing 
(PRN), which determines the prospective nursing time needed per patient based on a validated 
249-item list [25]. The housing costs were calculated per day of hospitalization. The 
administrative costs were counted per admission. Finally, the other costs covered the social 
work division, the priest, and the occupational therapy. Detailed data were furnished by the 
account department of our hospital and represented the real costs of each patient case. 
 All costs were primarily in Swiss Francs (CHF). The used exchange rate to euros (€) 
was the one current on March 8, 2015: CHF1=€0.94. No correction for general price 
difference between the two periods (ERAS and pre-ERAS) was made. 
Cost-minimization analysis and sensitivity analysis 
 A cost-minimization analysis was performed, i.e., hospital savings per patient were 
calculated. This present analysis was made by the subtraction of the standard care costs per 
patient to the ERAS-specific costs per patient and the ERAS costs per patient. The ERAS-
specific costs included the salary of the ERAS-dedicated nurse (fixed costs), the costs of the 
quarterly ERAS liver meetings (fixed costs), the ERAS database (variable costs, depending on 
the patient number), the patient carbohydrates drinks (variable costs, depending on the patient 
number), and the patient logbook costs (variable costs, depending on the patient number).  
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 A sensitivity analysis was undertaken as well. As fixed costs are independent from the 
patient number and are allocated on an individual basis, large variations due to the number of 
patients can appear. We therefore calculated the cost-minimization by varying the patient 
number by ±50% (i.e., calculating the ERAS-specific costs for 37 and 111 patients). 
Subgroup analysis 
 A subgroup analysis was performed for all hepatic resections that were performed by 
laparotomy. Mean total costs were calculated and compared using a bootstrap T-test.  
Statistical analysis 
 A Mann-Whitney U test or a T-test was used to compare continuous variables 
depending on the distribution type and the homogeneity of the variances. Categorical 
(discrete) variables were compared using a Fisher’s exact test or a Chi-square test. The 
arithmetic means were used because they represent informative and explicit figures from a 
pharmaco-economic standpoint. Moreover, a resampling was performed for the cost analysis 
by using the bootstrap method because of its simplicity, its property to derive confidence 
intervals from a complex sample distribution, and its robustness of estimation. A bootstrap T-
test was used to compare the different costs. A p-value <0.05 was considered statistically 
significant. Statistical analyses were performed using SPSS®19 (IBM, Armonk, New York, 
USA) and GraphPad Prism©5.  
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Results 
Patient characteristics and surgical details  
 A total of 174 patients were enrolled for further analysis: 74 in the ERAS group and 
100 in the pre-ERAS group. Demographic, preoperative, and surgical data were comparable 
in the ERAS and pre-ERAS groups, except for laparoscopy that was more frequently 
performed in the ERAS group (n=18 vs. n=9, p=0.010). Table 2 resumes the patient 
characteristics and the surgery type performed. 
Compliance and perioperative outcomes  
 In terms of compliance to the ERAS protocol, the overall rate including all pre-, intra-, 
and postoperative ERAS items was 73.8% in the ERAS group compared to 48.7% in the pre-
ERAS group (p<0.001). The readmission rate 60 days after the operation was not significantly 
different between the two groups (6/74=8% and 7/100=7%, p=0.780).  
 The perioperative data are summarized in Table 3. There was no difference in the 
operating time and the anesthesia time between the ERAS and pre-ERAS groups. The overall 
complication rate was significantly lower in the ERAS group compared to the pre-ERAS 
group (36/74=49% vs. 64/100=64%, p=0.046). If one subdivides the complications into minor 
(I-II) and major (III-IV) there were no differences between the ERAS and pre-ERAS groups. 
Median CCI was lower for the ERAS group (8.7 vs. 20.9, p=0.044). The median LoS was 
significantly shorter for the ERAS group (8 vs. 10 days, p=0.006). The median ICU stays 
were 0 and 1 day for the ERAS and pre-ERAS groups (p<0.001), while the median IC stays 
were 2 and 3 days (p=0.002), respectively.  
Analysis of the costs  
 The mean (SD) total costs/patient were €38’726 (31’608) for the ERAS group and 
€42’356 (26’898) for the pre-ERAS group (p=0.467). The mean intraoperative costs/patient 
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for the ERAS and pre-ERAS groups were €10’793 (6’228) and €9’981 (4’440) respectively 
(p=0.236). The mean pre-/postoperative costs/patient were €27’933 (27’635) for the ERAS 
group and €32’375 (25’224) for the pre-ERAS group (p=0.271). The pre-, intra- and 
postoperative costs are summarized in detail in Table 4 and Figure 1. All mean costs/patient 
were lower for the ERAS group except for the anesthesia and OR, the nursing care, the 
housing, the administration, and the social service, occupational therapy and priest costs.  
Cost-minimization analysis and sensitivity analysis 
 The difference of mean total costs/patient between the pre-ERAS and ERAS groups 
was €3’630 (-9%), meaning that the total mean costs of ERAS/patient were €3’630 less 
expensive than the ones of the pre-ERAS group. 
 In the ERAS-specific costs, fixed ERAS costs included the crude salary of the ERAS-
dedicated nurse (€81’845 per year) and the costs of the ERAS liver meetings (€50/meeting for 
the used material and the preparation time, at least 4 meetings/year). As the ERAS-dedicated 
nurse was also responsible for ERAS colorectal and ERAS pancreas during the same period 
of time, we divided her salary by three. Fixed ERAS costs/patient were therefore: 
27’282/74+200/74=€371. The variable ERAS costs were the ERAS database (€100/patient), 
the patient carbohydrate drinks (€75/patient), and the patient logbooks (€4/patient). ERAS-
specific costs were thus calculated to be €550/patient. 
 The final total gain/patient for the ERAS group was €3’080 (-7%).  
 If we vary the number of patients by ±50%, the ERAS-specific costs/patient would be 
€922 for 37 patients and €427 for 111 patients, leading to a final total gain for ERAS/patient 
of €2’708 (-6%) and €3’203 (-8%), respectively. 
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Subgroup analysis 
 Regarding the operations performed by laparotomy, there were 55 patients in the 
ERAS group and 92 patients in the pre-ERAS group. Both groups showed similar 
demographics and surgical details. The total mean costs/patient was €42’234 (39’526) for the 
ERAS group and €45’584 (35’985) for the pre-ERAS group (difference: €3’350, p=0.657). 
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Discussion 
 The present study assessing the real costs of implementation of an ERAS protocol for 
liver surgery demonstrated in our cohort a non-significant decrease in costs compared to 
standard management but a significant decrease in complications and LoS.  
 The main savings engendered by the implementation of ERAS for liver surgery were 
found in the ICU/IC costs (€2’578/patient), but were not statistically significant (p=0.174). 
The majority of patients included in the ERAS protocol did not need to stay in the ICU, while 
the median length of ICU stay was one day for the pre-ERAS group (p<0.001). Moreover, the 
reduction of ICU stay for the ERAS group was also coupled to a shorter IC stay compared to 
the pre-ERAS group (2 vs. 3 days, p=0.002). This cannot be explained by a difference of 
operation complexity (major vs. minor hepatectomy) as the ERAS and pre-ERAS groups were 
similar in this regard (p=0.643) and the operation durations were comparable (p=0.188). With 
ERAS liver implementation, patients were routinely scheduled for IC unit if needed, or for the 
standard ward. Only in rare case of extended major hepatectomy, patients were 
postoperatively transferred to the ICU. The fact that IC unit stay was also shorter for the 
ERAS group suggests an enhanced recovery in the early postoperative days and a lower rate 
of patients necessitating continuous monitoring. This could be related to the standardized 
anesthesia protocol that emphasized the postoperative analgesia, the postoperative nausea and 
vomiting prophylaxis, the fluid intake, and the early diet, and/or to the standardized care maps 
guiding the postoperative phase [26,27]. 
 The second main absolute gain in the ERAS group but not statistically significant was 
related to the medical care costs (€1’052/patient). This can be linked, if there is a gain as it 
was not significant, to the reduced overall complication rate and LoS observed in the ERAS 
group. A postoperative complication results in increased medical resources (consultation, 
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non-surgical procedures, etc), therefore increasing the medical care costs [28,29]. ERAS also 
had a significant cost-benefit effect on the radiology and a non statistically significant cost-
benefit effect on the medication. The radiology costs represented the main statistically 
significant savings of the ERAS group with a gain of €558/patient (p=0.021). In the ERAS 
group, fewer medications were used and fewer radiological exams were performed 
postoperatively. These can be an effect of the implementation of ERAS, can be due to the 
diminution of postoperative complications, or can just be due to the standardization of the 
postoperative management with the clinical care maps [27], or a mix of the three previous 
explanations. Costs are frequently linked to LoS, and LoS differ widely from country to 
country. The most important factor for one country is the difference between the LoS before 
and after ERAS implementation rather than the absolute LoS. The same is true for ICU and 
IC stays that depend on local habits and infrastructures; the important point being the 
difference in ICU and IC needs before and after ERAS implementation more than the absolute 
numbers.  
 Conversely, the ERAS group had significantly higher anesthesia/OR costs and not 
significantly higher nursing care costs. As the anesthesia and OR times were not different 
between the two groups, the difference of costs mainly lies in the material and drugs used 
during anesthesia. The standardized anesthesia protocol and the routine prophylactic use of 
postoperative nausea and vomiting prevention by droperidol, ondansetron, and 
bethamethasone only explain a small part of this difference, as the prophylaxis costs are low. 
The higher number of laparoscopies in the ERAS group had no impact on the material and 
drugs used during anesthesia. Of note, the number of thoracic epidurals was similar in both 
groups (54/74 ERAS group vs. 79/100 pre-ERAS group, p=1). No clear explanation was 
therefore found for this increase in anesthesia and OR costs. Regarding the nursing care costs, 
as the ICU and IC median stays were shorter, the patients with higher PRN number (i.e., 
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representing the case complexity in terms of nursing actions) [25] were transferred earlier to 
the ward, therefore increasing this part of the costs at the beginning of their hospital stay.  
 LoS was found to be shorter for the ERAS group. There was nevertheless no 
repercussion on the mean housing costs/patient. No difference of mean housing costs was 
indeed found between the ERAS and pre-ERAS groups (p=0.058). This is explained by the 
constant annual increase (inflation) of the basal rate of hospital housing costs throughout the 
years. It is not clear why a diminution of complications and a shorter LoS did not translate 
into significant overall cost difference. One explanation could be related to the large found 
confidence intervals inherent to the bootstrap method and related to the p-value. It is 
nevertheless interesting to notice that implementation of ERAS had positive outcomes for the 
patients without increasing the costs, meaning that ERAS was cost-effective. This also 
justifies the investment costs necessary to implement ERAS.  
 ERAS for liver surgery was previously shown to be feasible and safe [12–15]. Two 
systematic reviews showed a decrease in complications and/or a reduction of LoS without an 
increase of the readmission rate, corroborating the results of this present study [18,19]. A 
study by Dunne et al. including hepatectomies for colorectal metastasis found that as ERAS 
experience increases with time, a progressive diminution of hospitalization time and critical 
care admission was noticed [30]. However, reduced LoS may be associated with higher rate 
of readmissions as reported by Connor et al. [11]. It has to be emphasized that the present 
study showed a significant shorter LoS after ERAS implementation, but the readmission rate 
did not increase and remained low. Hospital discharge was based on formal discharge criteria.  
 As shown by previous studies, implementation of ERAS protocols in gastrointestinal 
surgery needs initial investments, but is then associated with an important gain per patient for 
both financial and clinical aspects (significant diminution of complications, reduction of LoS, 
quicker recovery) [2,3,31–33]. Once the implementation phase is done, financial gains appear 
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and continue over time, giving considerable savings proportionally to the increasing number 
of patients included in the protocol. Regarding the real costs of the implementation of an 
ERAS pathway for liver surgery, data are for the moment non-existent. A simulation study 
from Faujour et al. was recently published and estimated that after ERAS implementation in 
different specialties, an overall gain of €180/hospital day for all the surgical units could be 
obtained [34]. In this study ERAS was implemented in five French units of digestive 
(including liver surgery), orthopedic, and urology surgeries. Their outcomes were based on 
estimations and not on real costs as in the present study. In our department, ERAS was 
already implemented in colorectal surgery since 2011, so costs of education and training of 
the team were not included in this analysis. 
 Comparing the overall cost data of this study to the results published for colorectal 
surgery [3], the absolute cost difference between ERAS and pre-ERAS is more important in 
liver surgery (€3’080 vs. €1’651). This is partly explained by the fact that the overall costs for 
liver surgery are higher than for colorectal surgery. The observed not significant overall cost 
difference between ERAS and pre-ERAS in the present study can be explained by the fact 
that even though there is an important absolute difference (i.e., €3’080) between the two 
groups, the relative difference is rather small (-7%). Nevertheless, the present study suggests 
benefits of ERAS implementation in liver surgery.   
 The present study has several limitations that must be addressed. First, the higher 
number of laparoscopies in the ERAS group may in part explain the results. Laparoscopy as 
single measure has been shown to improve and fasten recovery [35,36]. Therefore the higher 
percentage of laparoscopic cases in the ERAS group entails a bias, as we do not know exactly 
to which extent the benefits are due to ERAS, laparoscopy, standardization, or all together. To 
minimize this bias, a subgroup analysis was performed with the patients operated by 
laparotomy. The difference of total mean costs/patient between pre-ERAS and ERAS 
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(€3’350) was not different from the total mean costs calculated in the entire cohort (€3’620, 
laparotomy and laparoscopy patients). These findings support the fact that laparoscopy did 
not play a major role in the cost benefits observed in the ERAS group. Second, the ERAS and 
pre-ERAS groups were retrospectively analyzed inducing all possible limitations of a 
retrospective study (e.g., underreporting of complications, missing data). However, the data 
have been prospectively recorded in our liver database for several years, and the same 
database was used for both periods. Moreover, the validated Clavien classification of 
complications and the CCI were systematically used and provided a recognized objective 
evaluation of complications for both periods. Finally, only costs linked to the primary 
hospitalization were calculated (in-hospital costs), the costs for postoperative rehabilitation 
and recovery time before returning to work were not taken into account in the current 
analysis. However, despite the lack of actual data on rehabilitation after ERAS, it can be 
assumed that outpatient recovery may also become easier and faster in ERAS patients [37]. 
To support this statement discharge was based on formal pre-established criteria, and 
readmission rates were similar. 
 ERAS-skeptics may argue that it is difficult to differentiate between the positive 
benefits of the ERAS program itself and the systematization of care induced by the ERAS 
care maps. They are right, there is nothing magical in ERAS. However, care maps belong to 
ERAS programs with systematization of care, and the final goal achieved is of importance: a 
significant decrease in complication rate. Whether it comes from the pathophysiology of 
ERAS, from the systematization, or from both matters little but this deserves further 
investigation beyond the present study aim. Of note, the ERAS-specific costs of this present 
analysis were half of the ones that were published for implementation of ERAS in colorectal 
surgery [3] because the costs of the courses to educate the team to the ERAS concept were not 
necessary and therefore not included. Finally, one can challenge if Swiss results may be 
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extrapolated to other countries. In fact, the importance of the present results lies in the cost, 
complication rate, and LoS differences between pre- and after ERAS implementation more 
than in the absolute numbers. For this reason, it can be suggested that the present outcomes 
may also be observed in other countries. 
 In conclusion, implementation of ERAS for liver surgery showed a non-significant 
decrease in costs in our institution. It also led to a significant reduction of the overall 
complication rate and LoS.  
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Table 1. ERAS protocol for liver surgery used in our department compared to the pre-ERAS 
period.  
* Preadmission counseling is performed by the ERAS-dedicated nurse and consists mainly of information on the 
ERAS protocol and the patient logbook. PONV: postoperative nausea and vomiting. IV: intravenous. LMW: low 
molecular weight. IPC: intermittent pneumatic compression. POD: postoperative day. NSAIDs: nonsteroidal 
anti-inflammatory drugs.
ERAS single item ERAS protocol Pre-ERAS period 
Preoperative   
Counseling and education 
Preadmission counseling and 
written information at the 
outpatient clinic* 
None 
Fasting Clear fluids until 2h before surgery, solids 6h before surgery 
Clear fluids and solids 6h before 
surgery 
Carbohydrate drinks 800 ml the evening before surgery and 400 ml 2h before surgery None 
Premedication No premedication Anesthesiologist-dependant 
Thromboprophylaxis LMW heparin 12h before surgery and during hospitalization, and IPC 
LMW heparin 12h before surgery 
and during hospitalization 
Oral bowel preparation No routine use No routine use 
Intraoperative   
PONV prophylaxis 
Droperidol + ondansetron +/- 
bethamethasone if no 
contraindication 
No routine use 
Hypothermia prevention Active warming with air blanket Active warming with air blanket. 
Antibiotic prophylaxis Cefuroxime 1.5 g at induction Cefuroxime 1.5 g at induction 
Balanced IV fluids 
Intraoperative crystalloids quantity 
depending on the operation 
avoiding salt and water overload. 
Postoperative crystalloids 1000 ml 
for the first 24h then 500 ml/24h 
for the first postoperative days 
No policy 
Postoperative   
Nasogastric tube No routine use No routine use 
Postoperative analgesia 
Epidural or systemic morphine and 
paracetamol (if no hepatic failure) 
and metamizole. Oral oxycodone-
naloxone (when epidural is 
removed, usually on POD 3). 
NSAIDs from POD 5 instead of 
metamizole 
No routine use of epidural 
Abdominal drains No routine abdominal drainage Surgeon-dependant 
Urinary catheter Removal on POD 3 Removal depending on the surgeon 
Nutrition 
Free fluids 4h after surgery. 
Normal diet from POD 1. Two 
nutritional supplements per day 
Free fluids on day 1, then 
depending on the patient’s 
evolution 
Laxatives Oral magnesium hydroxide twice a day until day of hospital discharge No routine use 
Mobilization 
Out of bed at least 2h on the day of 
surgery. From POD 1 at least 8h 
out of bed 
No protocol 
Systematic audit Systematic audit, meeting every 3 months None 
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Table 2. Patient demographics and surgical details. 
 ERAS group (n=74) Pre-ERAS group (n=100) P-value 
Age (years)* 60.5 (50-68.25) 64 (57.25-69.75) 0.061 
Gender (W/M) 31 (42%)/43 (58%) 40/60 0.876 
Body mass index (kg/m2) 25.3 (21.6-29) 24.8 (22.3-27.8) 0.812 
ASA score I-II/III† 56 (76%)/18 (24%) 72/28 0.607 
Active smokers 19 (26%) 26 1.000 
No alcohol consumption 36 (49%) 59 0.218 
Cirrhosis 4 (5%) 12 0.186 
Diabetes 14 (19%) 19 1.000 
Immunosuppression 4 (5%) 1 0.165 
Preoperative chemotherapy 29 (39%) 54 0.066 
Preoperative PV embolization‡ 11 (15%) 26 0.092 
Preoperative bile duct stenting 4 (5%) 3 0.460 
Open/laparoscopy 56 (76%)/18 (24%) 91/9 0.010 
Hepatectomy** 
Major 
Minor 
Wedge resection 
 
30 (41%) 
36 (49%) 
8 (10%) 
 
45 
44 
11 
 
0.643 
0.643 
1.000 
WHO performance§ 
0/1/2/3/4 
 
31 (42%)/40 (54%)/2 (3%)/1 (1%) 
 
56/42/1/1 
 
0.288 
Diagnoses 
HCC¶ 
Colorectal metastasis 
Cholangiocarcinomas 
Other cancers 
Benign lesions# 
 
10 (14%) 
31 (42%) 
9 (11%) 
4 (5%) 
20 (28%) 
 
16 
46 
9 
13 
16 
 
0.675 
0.645 
0.616 
0.123 
0.090 
* Medians are expressed with interquartile range. † American Society of Anesthesiologists score. ‡ PV: portal 
vein. ** Major hepatectomy was defined as resection of 3 or more Couinaud segments. § World Health 
Organization perfomance index: 0=asymptomatic, 1=symptomatic, ambulant, 2=symptomatic, <50% in bed, 
3=symptomatic, >50% in bed, 4=bedbound. ¶ Hepatocellular carcinomas. # Benign lesions included adenomas, 
cystadenomas, echinococcosis, biliary cysts, and polycystic liver diseases.  
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Table 3. Perioperative outcomes. 
 ERAS group (n=74) Pre-ERAS group (n=100) P-value 
Operating time, min* 254.5 (188.3-351) 279 (208-359) 0.188 
Anesthesia time, min 354 (273.3-436.8) 375 (300-454.5) 0.115 
Pedicular clamping 45 (61%) 53 0.355 
Complications 
Minor (I-II) 
Major (III-IV) 
Deaths (V) 
36 (49%) 
25 (34%)  
10 (14%) 
1 (1%) 
64 
42 
20 
2 
0.046 
0.345 
0.313 
1.000 
CCI† 8.7 (0-21.3) 20.9 (0-29.6) 0.044 
Length of stay, days 8 (6-11) 10 (7-15.5) 0.006 
ICU stay, days‡ 0 (0-0) 1 (0-2) <0.001 
IC stay, days** 2 (1-3.25) 3 (2-4) 0.002 
Overall compliance (%)§ 73.8 (52.4-89.1) 48.7 (37.4-59.3) <0.001 
Readmission at 60 days 6 (8%) 7 0.780 
 
*Medians are expressed with interquartile range. †Comprehensive complication index. ‡Intensive care unit. 
**Intermediate care. §Overall compliance represents the number of fulfilled items divided by the total number of 
enhanced recovery measures (%). 
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Table 4. Detailed costs for the ERAS and pre-ERAS groups in euros. 
 
  ERAS  Pre-ERAS     
  Mean (SD) 
Inferior 
CI 
Superior 
CI Mean (SD) 
Inferior 
CI 
Superior 
CI 
Mean 
difference 
Inferior 
CI 
Superior 
CI P-value 
Total intraoperative 10 793 (6 228) 9 399 12 668 9 981 (4 440) 8 797 11 332 812 -1 322 3 190 0.236 
 
Disposable 
materials 1 923 (1 468) 1 595 2 304 2 675 (3 510) 2 058 3 418 
 
-752 -1 545 -44 0.079 
 
Anesthesia and 
operating room 8 870 (5 208) 7 804 10 364 7 306 (3 235) 6 740 7 914 1 564  223 3 234 0.039 
            
Total pre- and 
postoperative 27 933 (27 635) 18 722 40 146 32 375 (25 224) 24 840 41 456 -4 442 -17 980 9 958 0.271 
 ICU/IC 5 754 (12 365) 3 509 8 960 8 332 (12 704) 6 190 10 970 -2 578 -6 092 1 296 0.174 
 Medical care 9 015 (18 459) 5 397 13 748 10 067 (15 072) 7 338 13 361 -1 052 -6 283 4 252 0.709 
 Nursing care 4 986 (5 289) 3 913 6 308 4 185 (3 251) 3 547 4 898 801 -437 2 343 0.242 
 Physiotherapy 500 (710) 304 787 607 (699) 471 769 -106 -364 201 0.452 
 Medication 1 232 (3 142) 675 2 039 2 008 (3 013) 1 515 2 688 -776 -1 641 198 0.091 
 Blood 538 (1 281) 308 857 827 (1 847) 523 1 235 -290 -743 194 0.252 
 Laboratory 1 430 (1 862) 1 060 1 898 1 861 (1 987) 1 480 2 269 -431 -990 172 0.158 
 Radiology 701 (1 322) 422 1 025 1 259 (1 857) 912 1 630 -558 -1 018 -81 0.021 
 Pathology 1 293 (997) 1 085 1 540 1 312 (757) 1 177 1 475 -19 -299 271 0.882 
 Housing 1 964 (1 818) 1 586 2 385 1 480 (1 004) 1 281 1 689 484 30 939 0.058 
 Administration 415 (0) 415 415 347 (46) 338 357 67 58 77 0.001 
 Others* 105 (289) 50 184 89 (125) 68 116 16 -47 95 0.659 
            
Total 38 726 (31 608) 28 121 52 814 42 356 (26 898) 33 638 52 788 -3 630 -19 302 13 148 0.467 
 
ICU: intensive care unit, IC: intermediate care, SD: standard deviation, CI: 95% confidence interval. 
* Others included the social work, the chaplain/priest, and the occupational therapy costs. 
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Figure 1. Box-Whisker plots of intraoperative, pre-/postoperative, and total mean cost 
differences between the two groups (ERAS minus pre-ERAS) in euros. 
 
        
 
     
